Acuitas AMR Gene Panel (ucp)
Urinary tract infection (UTI) pathogen ID & resistance detection
FDA SubmissionUnder FDA Review
Key Facts
Indication
Urinary tract infection (UTI) pathogen ID & resistance detection
Phase
FDA Submission
Status
Under FDA Review
Company
About OpGen
OpGen is a US-based public company focused on addressing the global antimicrobial resistance (AMR) crisis through advanced diagnostics and data analytics. Its core offerings include the Acuitas AMR Gene Panel and the Unyvero platform for rapid detection of pathogens and resistance markers. The company's strategy involves integrating molecular diagnostics with bioinformatics to guide targeted antibiotic therapy and support infection control programs in hospitals.
View full company profile